ALK and non-small cell lung carcinoma: In NSCLC tumors with other oncogenic alterations, this aberrant activation of PI3K/AKT or MAPK pathways has already been described as a mechanism of resistance to chemotherapy, targeted therapies, and radiotherapy [67–70], but to our knowledge this is the first time that this dual reactivation is described as a resistance mechanism to ALK inhibitors.